Kamal D Srivastava1, Alyssa Siefert2, Tarek M Fahmy3, Michael J Caplan4, Xiu-Min Li1, Hugh A Sampson5. 1. Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY; Jaffe Food Allergy Institute, New York, NY. 2. Department of Biomedical Engineering, Yale University, New Haven, Conn. 3. Department of Biomedical Engineering, Yale University, New Haven, Conn; Department of Immunobiology, Yale University School of Medicine, New Haven, Conn. 4. Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, Conn. 5. Pediatric Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY; Jaffe Food Allergy Institute, New York, NY. Electronic address: hugh.sampson@mssm.edu.
Abstract
BACKGROUND: Treatments to reverse peanut allergy remain elusive. Current clinical approaches using peanut oral/sublingual immunotherapy are promising, but concerns about safety and long-term benefit remain a barrier to wide use. Improved methods of delivering peanut-specific immunotherapy are needed. OBJECTIVE: We sought to investigate the efficacy and safety of peanut oral immunotherapy using CpG-coated poly(lactic-co-glycolic acid) nanoparticles containing peanut extract (CpG/PN-NPs) in a murine model of peanut allergy. METHODS: C3H/HeJ mice were rendered peanut allergic by means of oral sensitization with peanut and cholera toxin. Mice were then subjected to 4 weekly gavages with CpG/PN-NPs, vehicle (PBS), nanoparticles alone, peanut alone, CpG nanoparticles, or peanut nanoparticles. Untreated mice served as naive controls. After completing therapy, mice underwent 5 monthly oral peanut challenges. Anaphylaxis was evaluated by means of visual assessment of symptom scores and measurement of body temperature and plasma histamine levels. Peanut-specific serum IgE, IgG1, and IgG2a levels were measured by using ELISA, as were cytokine recall responses in splenocyte cultures. RESULTS: Mice with peanut allergy treated with CpG/PN-NPs but not vehicle or other treatment components were significantly protected from anaphylaxis to all 5 oral peanut challenges, as indicated by lower symptom scores, less change in body temperature, and a lower increase of plasma histamine levels. Importantly, CpG/PN-NP treatment did not cause anaphylactic reactions. Treatment was associated with a sustained and significant decrease in peanut-specific IgE/IgG1 levels and an increase in peanut-specific IgG2a levels. Compared with vehicle control animals, peanut recall responses in splenocyte cultures from nanoparticle-treated mice showed significantly decreased levels of TH2 cytokines (IL-4, IL-5, and IL-13) but increased IFN-γ levels in cell supernatants. CONCLUSIONS: Preclinical findings indicate that peanut oral immunotherapy with CpG/PN-NPs might be a valuable strategy for peanut-specific immunotherapy in human subjects.
BACKGROUND: Treatments to reverse peanutallergy remain elusive. Current clinical approaches using peanut oral/sublingual immunotherapy are promising, but concerns about safety and long-term benefit remain a barrier to wide use. Improved methods of delivering peanut-specific immunotherapy are needed. OBJECTIVE: We sought to investigate the efficacy and safety of peanut oral immunotherapy using CpG-coated poly(lactic-co-glycolic acid) nanoparticles containing peanut extract (CpG/PN-NPs) in a murine model of peanutallergy. METHODS: C3H/HeJ mice were rendered peanut allergic by means of oral sensitization with peanut and cholera toxin. Mice were then subjected to 4 weekly gavages with CpG/PN-NPs, vehicle (PBS), nanoparticles alone, peanut alone, CpG nanoparticles, or peanut nanoparticles. Untreated mice served as naive controls. After completing therapy, mice underwent 5 monthly oral peanut challenges. Anaphylaxis was evaluated by means of visual assessment of symptom scores and measurement of body temperature and plasma histamine levels. Peanut-specific serum IgE, IgG1, and IgG2a levels were measured by using ELISA, as were cytokine recall responses in splenocyte cultures. RESULTS:Mice with peanutallergy treated with CpG/PN-NPs but not vehicle or other treatment components were significantly protected from anaphylaxis to all 5 oral peanut challenges, as indicated by lower symptom scores, less change in body temperature, and a lower increase of plasma histamine levels. Importantly, CpG/PN-NP treatment did not cause anaphylactic reactions. Treatment was associated with a sustained and significant decrease in peanut-specific IgE/IgG1 levels and an increase in peanut-specific IgG2a levels. Compared with vehicle control animals, peanut recall responses in splenocyte cultures from nanoparticle-treated mice showed significantly decreased levels of TH2 cytokines (IL-4, IL-5, and IL-13) but increased IFN-γ levels in cell supernatants. CONCLUSIONS: Preclinical findings indicate that peanut oral immunotherapy with CpG/PN-NPs might be a valuable strategy for peanut-specific immunotherapy in human subjects.
Authors: Carlos Gamazo; Carmen D'Amelio; Gabriel Gastaminza; Marta Ferrer; Juan M Irache Journal: Hum Vaccin Immunother Date: 2017-10-03 Impact factor: 3.452
Authors: Kyle J Bednar; Lakeya Hardy; Johanna Smeekens; Dharmendra Raghuwanshi; Shiteng Duan; Mike D Kulis; Matthew S Macauley Journal: J Vis Exp Date: 2018-10-25 Impact factor: 1.355
Authors: Brandi T Johnson-Weaver; Susan McRitchie; Kelly A Mercier; Wimal Pathmasiri; Susan J Sumner; Cliburn Chan; Dori Germolec; Michael Kulis; A Wesley Burks; Herman F Staats Journal: J Allergy Clin Immunol Date: 2017-09-18 Impact factor: 10.793
Authors: Matthew T Walker; Jeremy E Green; Ryan P Ferrie; Ashley M Queener; Mark H Kaplan; Joan M Cook-Mills Journal: J Allergy Clin Immunol Date: 2018-02-15 Impact factor: 10.793
Authors: Michelle L Bookstaver; Shannon J Tsai; Jonathan S Bromberg; Christopher M Jewell Journal: Trends Immunol Date: 2017-12-14 Impact factor: 16.687